Vaxcyte (PCVX), What Is Behind The Fresh Attention?
Vaxcyte’s OPUS-1 data puts VAX-31 in focus
Vaxcyte (PCVX) just cleared a key hurdle for its VAX-31 pneumococcal vaccine candidate, reporting that the Phase 3 OPUS-1 trial met all prespecified co-primary immunogenicity endpoints with a safety profile described as comparable to existing vaccines.
For context, Vaxcyte shares trade at US$67.55 after a 13.45% 1 month share price return and a 45.39% year to date share price gain, while total shareholder return over the past year is 53.73% and over five years is about 3x. This suggests momentum has been building as OPUS-1 data and the recent US$500m follow on equity and US$500m convertible note offerings reshaped expectations for both funding and future execution.
Scan beyond Vaxcyte and see how other vaccine and healthcare specialists compare on quality and valuation inside our hand picked 34 healthcare AI stocks
After a sharp rerating on OPUS-1 and the twin US$500m raises, Vaxcyte now trades as if much of the good news is already captured. How much potential may still be reflected in current expectations?
Most Popular Narrative: 41% Undervalued
On the most followed narrative, Vaxcyte’s fair value sits at about $114.78 against a last close of $67.55. The story being modeled assumes a lot more upside than the current quote implies and leans heavily on what OPUS-1 means for VAX-31’s future in adult pneumococcal vaccines.
Vaxcyte is a vaccine company focused on developing broader-coverage pneumococcal and Group A Strep vaccines for adult and pediatric use. Multiple ongoing late stage VAX-31 adult trials and the planned BLA package are aligned with existing FDA frameworks for pneumococcal vaccines.
See why 2 investors see Vaxcyte as 41% undervalued.
Result: Fair Value of $114.78 (UNDERVALUED)
Still, this narrative leans on successful VAX-31 approvals and uptake, plus disciplined spending, so any clinical setback or faster cash burn could quickly reframe Vaxcyte expectations.
Find out about the key risks to this Vaxcyte narrative.
Next Steps
Mixed signals or clear opportunity, the only view that really matters is yours. Move quickly, review the data from both sides, and weigh up the 2 key rewards and 4 important warning signs.
Looking for more Vaxcyte sized opportunities?
If Vaxcyte has sharpened your appetite for high conviction ideas, do not stop here. Broader context across sectors can refine your next move.
Use the Simply Wall Street screener to stress test your approach against other types of opportunities so you are not relying on a single story.
- Target fresh upside potential by scanning a 20 high quality undiscovered gems that could sit off the usual radar yet still pass solid fundamental checks.
- Prioritise resilience first and filter for a 32 resilient stocks with low risk scores that keeps balance sheet strength and lower volatility front and center.
- Lock in a focus on financial sturdiness by working through a list of solid balance sheet and fundamentals (25 results) that keeps cash, debt, and core quality in clear view.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com